<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00280540</url>
  </required_header>
  <id_info>
    <org_study_id>CVAH631BUS05</org_study_id>
    <nct_id>NCT00280540</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension</brief_title>
  <official_title>A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy (160 mg) or Combo Therapy (Valsartan + Hydrochlorothiazide, 160/12.5 mg) to Conventional Low-dose Valsartan Monotherapy (80 mg) in Managing Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a double-blind study to evaluate the reduction in systolic blood pressure using a
      therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg
      compared to a more conventional approach (therapy initiated with low-dose valsartan 80 mg).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline systolic blood pressure after 4 weeks</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline systolic blood pressure after 2 and 6 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time in weeks to achieve blood pressure less than 140/90 mmHg over 6 week period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure less than 140/90 mmHg after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline diastolic blood pressure after 6 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood and urine markers after 6 weeks</measure>
  </secondary_outcome>
  <enrollment>648</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan/Hydrochlorothiazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 or older

          -  Diagnosed as having hypertension (mean seated systolic blood pressure ≥ 150 mm Hg but
             &lt; 180 mm Hg and mean seated diastolic blood pressure ≥ 90 mm Hg and &lt;110 mm Hg)

        Exclusion Criteria:

          -  Patients with severe hypertension: Systolic ≥ 180 mm Hg or Diastolic ≥ 110 mm Hg

          -  History of secondary hypertension (including primary aldosteronism, renovascular
             hypertension, pheochromocytoma etc.)

          -  History of myocardial infarction, stroke [e.g. cerebrovascular accident (CVA),
             thrombotic stroke, transient ischemic attack (TIA)], or onset of heart failure within
             the last 6 months.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2006</study_first_submitted>
  <study_first_submitted_qc>January 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2006</study_first_posted>
  <last_update_submitted>November 5, 2010</last_update_submitted>
  <last_update_submitted_qc>November 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2010</last_update_posted>
  <keyword>Hypertension</keyword>
  <keyword>High blood pressure</keyword>
  <keyword>Blood pressure control</keyword>
  <keyword>Blood pressure reduction</keyword>
  <keyword>Valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

